dTpa

Phase 3

GSK plc (GSK)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Nov '26

GSKPhase 3$100.5B

dTpa Phase 3 Est. Readout

dTpa• Diphtheria-Tetanus-acellular Pertussis Vaccines102

Nov 2026~Estimated

CT.gov

00%

Competitive Landscape

0 competitors in Diphtheria-Tetanus-acellular Pertussis Vaccines

View Full Landscape

Drug Information

Target Indication

Diphtheria-Tetanus-acellular Pertussis Vaccines

Clinical Trial

NCT07596199

Last updated: 11/4/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

GSK

GSK plc

Pharmaceutical Preparations•Europe•NYSE

Related Pipeline

Combined Hepatitis A and B vaccinePhase 3

Hepatitis B

GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)Phase 3

Infections, Meningococcal

62.5/25mcgPhase 3

Pulmonary Disease, Chronic Obstructive

FluoridePhase 3

Dental Caries

Haemophilus influenzae type b- and meningococcal (vaccine)Phase 3

Haemophilus Influenzae Type b

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts